No abstract available.
Mitral Valve ; Septal Occluder Device

No Abstract available.
Heart Septal Defects, Atrial* ; Septal Occluder Device*

Background:Persistent ductus arteriosus is a common congenital cardiac disease. If it isn't diagnosed and treated on time, the patient will be suffered severe complication which can cause mortality. The surgery for ductus arteriosus closure is a treatment method which is being applied at many Surgery Center in our country. Objectives:This study aims to evaluate the results of transcatheter patent ductus arteriosus closure using amplatzer duct occluders in children admitted into national hospital of pediatrics. Subjects and method: A prospective study was carried out on 40 children with patent ductus arteriosus confirmed by echocardiography in National Hospital of Pediatrics from October 2005 to October 2006. Transcatheter closure by amplatzer was used in all patients. Changes in clinical, laboratory findings and particularly Echocardiography were obtained before and after treatment. Results: The mean age and weight of the patients were 44.86 \xb1 41.11 months and 12.44 \xb1 6.5 kg. Closure was successful in 38/40 patients (95%), complications occurred in one patient (2.5%), no death was occurred. The rate shunting was 15% after 1 day and 0% after 3 months. Conclusion: Transcatheter closure using the Amplatzer was an effective and safe treatment for patent ductus arteriosus in pediatric patients.
Ductus Arteriosus/ physiopathology ; Septal Occluder Device ; Child

The Gerbode shunt, known as the left ventricle to the right atrial communication, is a rather rare finding, following surgical closure of septal defects. Even though the surgical closure is accepted as a treatment of choice, we report a successful percutaneous transcatheter closure of the Gerbode shunt in a 3-months old baby who weighed 3 kilograms.
Heart Septal Defects ; Heart Ventricles ; Humans ; Septal Occluder Device

Percutaneous device closure of secundum atrial septal defect (ASD) has become a definite therapy in selected patients. However the more transcatheter device was implanted, the more complication was developed. Especially, the device embolization remains a major complication requiring immediate intervention. We report a case of a displaced ASD occluder in the ascending aorta. We were successfully removed the device through a total circulatory arrest and closed the ASD.
Aorta* ; Heart Septal Defects, Atrial ; Humans ; Septal Occluder Device*

Humans ; Aortopulmonary Septal Defect/surgery* ; Septal Occluder Device

Humans ; Aortopulmonary Septal Defect/surgery* ; Septal Occluder Device

A 77-year-old female patient underwent aortic valve replacement (AVR) with concomitant septal myectomy and tricuspid annuloplasty. Her symptoms did not improve after a successful operation. Echocardiogram demonstrated the presence of an iatrogenic ventricular septal defect (VSD). It was muscular in location and not the usual AVR with membraneous type of VSD, suggesting a complication from the myectomy. Percutaneous closure of the VSD remained the only feasible option due to her poor overall medical status. A 14-mm Amplazter VSD occluder was deployed successfully, by means of the trans-septal technique. She has improved very well postoperatively.
Aged ; Aortic Valve* ; Female ; Heart Septal Defects ; Heart Septal Defects, Ventricular* ; Humans ; Septal Occluder Device

Percutaneous device closure of atrial septal defect (ASD) has proven to be safe and effective, and become a widely accepted option to the surgical repair. However, the embolization of Amplatzer septal occluder (ASO) occurs in about 0.55% to 3.5% of cases, regardless of ASD size, device size, or the physician's expertise. We report a case of embolization of an ASO into the thoracic descending aorta, successfully removed through a surgical approach.
Aorta, Thoracic ; Echocardiography, Transesophageal ; Heart Septal Defects, Atrial ; Septal Occluder Device

PURPOSE: This study was performed to compare the safety, efficacy and clinical results of the Amplatzer septal occluder (ASO) for closure of secundum atrial septal defect (ASD) with surgery. METHODS: One hundred fifteen patients diagnosed as isolated secundum ASD in Gil Medical Center, Gachon University of Medicine from January 2000 to July 2006 were included. Seventy patients underwent surgical repair of ostium secundum ASD. Forty-five consecutive patients were treated with percutaneous closure using ASO. We compared the mortality, morbidity, hospital stay, and efficacy between two groups. RESULTS: Male to female ratio was 1:2.4. The mean age and the size of defects were not statistically different. No mortality occurred in either group. The success rate was 97.8% in the device group and 100% in the surgical group. The overall rate of complications was higher in the surgical group than in the device group (64.0 vs. 15.6%, P<0.05). Hospital stay was shorter in the device group than in the surgical group (4.2+/-1.2 vs. 12.4+/-4.7 days, P<0.0001). Residual shunt rates were more frequent in the device group (8.9%) than in the surgical group (4.3%) at discharge. All residual shunts disappeared at 3 months follow-up. CONCLUSION: Percutaneous closure of ASD using ASO is a safe and effective alternative to surgical repair. The indications of percutaneous ASD closure with ASO would be expanded by accumulation of experiences and evolutions of device.
Female ; Follow-Up Studies ; Heart Septal Defects, Atrial* ; Humans ; Length of Stay ; Male ; Mortality ; Septal Occluder Device